Oxford Biomedica plc (LSE:OXB) shares rose 0.59% to 514.0p in the latest market screen, gaining 3.00p and taking the cell and gene therapy manufacturer's market capitalisation to around £619 million.
The shares have been stable since interim results in September, when the company reiterated guidance despite a revenue shortfall against forecasts.
Key Highlights
OXB reported H1 2026 revenue of £79.8 million, below analyst forecasts.
The company signed a record 17 new clients in the first half, more than 30% above the total signed in FY 2025, and its client programme portfolio grew 34%.
In August, OXB cut FY 2026 revenue guidance to £180-200 million, citing a shift in client ordering behaviour and phased ramp-up of its Durham, North Carolina site. Around £168 million is already covered by contracted orders.
OXB expects FY 2027 revenue growth of 25-30% and targets revenue of around £500 million by 2030, with long-term EBITDA margins approaching 30%.
About Oxford Biomedica plc
Oxford Biomedica plc (LSE:OXB) is a global quality and innovation-led cell and gene therapy CDMO (contract development and manufacturing organisation).
OXB manufactures viral vectors, including lentiviral and AAV vectors, for clients developing cell and gene therapies.
The company has expanded its global network, with its Durham, NC GMP manufacturing facility now online.
Why Is LSE:OXB Up Today?
The 0.59% rise to 514.0p does not appear to be tied to new company news. It likely reflects steady interest following the reiterated guidance.
Investors appear focused on the strong client wins and long-term growth targets rather than near-term revenue shortfalls.
The completed capacity build-out reduces future capital needs.
Key Reasons Behind the Uptick
One key factor is record client wins.
A second factor is reiterated guidance, with most FY 2026 revenue contracted.
Third, completed capacity expansion.
Fourth, long-term growth targets.
Key Growth Catalysts
The most important catalyst for LSE:OXB is delivery of FY 2026 guidance.
Revenue growth of 25-30% in FY 2027.
Programme progression to late-stage and commercial.
Durham, NC ramp-up.
Path to double-digit EBITDA margins.
Risks
The main risk for LSE:OXB is client ordering behaviour, which already caused a guidance cut.
Biotech funding conditions.
Execution risk in scaling sites.
Profitability: margins remain low.
Competition among CDMOs.
Valuation
At 514.0p, OXB has a market capitalisation of around £619 million. Valuation is based on long-term growth expectations.
The key valuation question is whether OXB can deliver its 2027 and 2030 targets.
Capital Returns
OXB does not pay a dividend and is investing in growth.
Capex is expected to normalise as network build is largely complete.
What Investors Should Watch Next
Investors in LSE:OXB will watch for year-end trading updates, client wins and margin progress.
Overall, the 0.59% rise in LSE:OXB to 514.0p reflects confidence in record client wins and long-term targets. At the same time, client ordering, biotech funding and profitability remain key risks.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...